Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Abbott Introduces Next Generation Laboratory Automation Solution to Help Meet Increased Testing Demand

Published: Wednesday, April 17, 2013
Last Updated: Wednesday, April 17, 2013
Bookmark and Share
Next generation automation solution designed to help labs process tests faster.

Abbott (NYSE: ABT) has announced the global launch of the ACCELERATOR® a3600, a next generation automation solution, to help laboratories address the need to process tests faster while handling increased volume. Advances in technology and automation within the lab have led to more timely results leading to improved patient care. Automation systems include the various instruments, devices, and software algorithms used in laboratories.

"As laboratories around the world face challenges due to staffing shortages, budget constraints, and increased demands, advances in automation technology such as Abbott's ACCELERATOR a3600 can help labs be more efficient and productive," said Brian Blaser, executive vice president, Diagnostics Products, Abbott. "Labs using automation can achieve more than 40 percent greater efficiency, helping them adapt to meet current and future demand, which is particularly important as approximately 70 percent of medical decisions are informed by diagnostic testing." 1,2

The ACCELERATOR a3600 is a laboratory automation track system that can process up to 3,600 samples per hour and handle multiple tube sizes and types simultaneously. By automating routine, manual tasks, this system may help labs reduce error and improve efficiency. Another advantage of the system is a modular design that offers labs the ability to install up to 99 combined analyzers and modules on a single system, which means that labs can address their testing needs today while planning for the future.

The ACCELERATOR a3600 automation solution, developed with Abbott partner Swiss-based Inpeco SA, is available worldwide pending country registration. To learn more about the role diagnostics can play in increasing quality and efficiency in labs, please click here.

Intended Use

The ACCELERATOR a3600 is a modular system designed to automate pre-analytical and post-analytical processing, sample-handling, and processing in the laboratory. The system consolidates multiple analytical instruments into a unified workstation by employing a common sample processing capability. Through communication connections among the automation system, analyzers, and the laboratory information system (LIS) or middleware, the automation software provides workload and sample-order management, as well as instrument operational status monitoring.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Abbott Completes Acquisition of Topera, Inc.
Company acquire all outstanding equity of Topera for $250 million upfront.
Tuesday, January 06, 2015
Abbott to Acquire Veropharm
The acquisition of the Russian pharmaceutical manufacturer is in keeping with the long term commitment to provide healthcare products to Russian patients.
Monday, June 23, 2014
Partners In Health, Abbott and the Abbott Fund Open Nutrition Facility in Haiti
Facility produces first shipments of locally sourced, therapeutic food to treat severe malnutrition in children.
Monday, November 11, 2013
Abbott Completes Separation of Research-Based Pharmaceuticals Business
Set to deliver industry-leading growth, expanding margins and strong cash flow.
Monday, January 07, 2013
Abbott's HUMIRA® (adalimumab) Receives U.S. FDA Approval
HUMIRA is now indicated to treat adult patients with moderate to severe ulcerative colitis who have had an inadequate response to immunosuppressants.
Thursday, October 04, 2012
Abbott to Collaborate with Astellas Pharma
The companies will collaborate in a Phase 3 clinical trial for ASP0113, an investigational vaccine for preventing cytomegalovirus reactivation in transplant patients.
Thursday, September 06, 2012
Leading Agent in the Treatment of Psosiasis
Abbott/Eisai's Humira has emerged on top with major-market sales of more than $1.4 billion in 2011.
Tuesday, August 07, 2012
Abbott Licenses Prostate Cancer Biomarkers
The exclusive license from Stanford University for several novel biomarkers could help develop a molecular diagnostic test that differentiates aggressive from nonaggressive prostate cancer.
Wednesday, April 18, 2012
Abbott Selects AbbVie as New Name for Future Research-Based Pharmaceutical Company
Abbott Remains on Track for Separation into Two Publicly Traded Global Health Care Companies by End of 2012
Thursday, March 22, 2012
Abbott's STARLIMS LIMS Technology to be Installed in FDA Testing Laboratories
FDA will begin implementing the software-based LIMS as part of the agency's initiative to enhance FDA testing laboratories by managing complex processes and analysing the vast amount of information generated.
Thursday, January 19, 2012
Abbott and University of Illinois Establish Center for Nutrition, Learning and Memory
The companies have established the first-ever multi-disciplinary nutrition and cognition research center,. The Center for Nutrition, Learning, and Memory will lead directed and solicited research on the impact of nutrition on learning and memory in the human brain.
Tuesday, December 20, 2011
Abbott and Reata Pharmaceuticals Announce Agreement for Next-Generation Antioxidant Inflammation Modulators
The companies announced that they have entered into a worldwide collaboration to jointly develop and commercialize Reata’s portfolio of second-generation oral antioxidant inflammation modulators (AIMs).
Wednesday, December 14, 2011
Abbott Expands Agreement with GSK to Include Development of a Companion Diagnostic Test
Companion diagnostic tests identify specific DNA sequences for cancer immunotherapy antigen.
Tuesday, November 29, 2011
FDA Approves First Supplemental Test for Chagas Disease
The U.S. Food and Drug Administration have approved the first test for use as an additional, more specific test on human serum or plasma specimens found to be positive for antibodies to T. cruzi, which causes Chagas disease, a serious and potentially fatal parasitic infection.
Monday, November 21, 2011
Abbott Presents Data Exploring Relationship of Physical Function to Inflammation and Structural Damage in Rheumatoid Arthritis
Abbott have presented results from a pooled analysis of two pivotal HUMIRA(R) (adalimumab) studies, which look at patients with early and long-standing moderate to severe rheumatoid arthritis (RA), at the American College of Rheumatology meeting in Atlanta. The study looked at inflammation and structural damage of the joints in early and long-standing RA and their relationship with deteriorating physical function in each stage of the disease.
Wednesday, November 17, 2010
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
New NIH-EPA Research Centers to Study Environmental Health Disparities
Scientists will partner with community organizations to study these concerns and develop culturally appropriate ways to reduce exposure to harmful environmental conditions.
Structure of Essential Digestive Enzyme Uncovered
Using a powerful combination of techniques from biophysics to mathematics, researchers have revealed new insights into the mechanism of a liver enzyme that is critical for human health.
Air Pollution Linked to Heart Disease
10-year project revealed air pollutants accelerate plaque build-up in arteries to the heart.
Getting a Better Look at How HIV Infects and Takes Over its Host Cells
A new approach, developed by a team of researchers led by The Rockefeller University and The Aaron Diamond AIDS Research Center (ADARC), offers an unprecedented view of how a virus infects and appropriates a host cell, step by step.
Following Tricky Triclosan
Antibacterial product flows through streams, crops.
Vitamin A May Help Improve Pancreatic Cancer Chemotherapy
The addition of high doses of a form of vitamin A could help make chemotherapy more successful in treating pancreatic cancer, according to an early study by Queen Mary University of London (QMUL).
Poverty Marks a Gene, Predicting Depression
New study of high-risk teens reveals a biological pathway for depression.
World’s Largest Coral Gene Database
‘Genetic toolkit’ will help shed light on which species survive climate change.
A Boost for Regenerative Medicine
Growing tissues and organs in the lab for transplantation into patients could become easier after scientists discovered an effective way to produce three-dimensional networks of blood vessels, vital for tissue survival yet a current stumbling block in regenerative medicine.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!